Breaking News

Financial Report: Akorn

By Kristin Brooks | March 3, 2014

Revenues up 19% in the quarter


4Q Revenues: $85.0 million (+19%)

4Q Earnings: $16.7 million (+89%)

FY Revenues: $317.7 million (+24%)

FY Earnings: $52.4 million (+48%)

Comments: In the quarter, the company announced the acquisition of Hi-Tech Pharmacal, expanding its branded ophthalmic portfolio, filed 12 ANDAs and completed the development of an additional 11 ANDAs, and completed the acquisition of the U.S. rights to three branded ophthalmic products from Merck: AzaSite, COSOPT and COSOPT PF. The company’s overall gross profit margin was down 6% due to a significant percentage of Akorn’s revenue growth coming from products that were contract manufactured, some of which include profit sharing arrangements with development partners.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus